Navigation Links
Cooperation in diabetes research
Date:10/18/2010

The recently signed cooperation agreement between the MPI of Biochemistry and GSK pursues the objective of developing innovative new drugs. The joint research and development work is based on the research findings of Axel Ullrich, Director at the MPI of Biochemistry. He and fellow scientist Mathias Bcker successfully described the role of certain protein molecules - known as kinases - in connection with the development of type II diabetes, a disease in which insulin resistance gives rise to a raised blood sugar level. These kinases make up a group of important signal molecules in the body, which can, under certain circumstances, be involved in the development or manifestation of the disease. In the collaborative project with GSK, the scientists are looking for new substances that can inhibit this kinase activity and control it in a targeted manner.

Axel Ullrich already achieved a milestone in the treatment of diabetes back in 1977, together with fellow scientists at the University of California. At that time, he developed a method of transferring a copy of the human insulin gene into bacteria. This facilitated the industrial manufacture of human insulin for the very first time and has since made it easier for millions of diabetics to live with the disease, as they no longer have to depend on animal insulin, which is not nearly so well tolerated by the human body.

Axel Ullrich's current research is set to contribute to the successful treatment of diabetes a second time. "Developing innovative drugs to treat diabetes gives us the opportunity to directly influence defects in the molecular signal paths, which lie at the root of diabetes. That enables us to fight the actual causes of diabetes," says Ullrich. Peter Gruss, President of the Max Planck Society expressed his delight with the collaboration agreement: "GlaxoSmithKline is one of the world's five major pharmaceutical companies. The collaboration agreement with GSK testifies to the fact that Max Planck Institutes, due to their leading edge in basic research, are also sought-after partners in industry. Max Planck researchers generate ideas for new approaches in application-oriented industrial research. We hope that together with a strong partner, we will be able to translate research findings into therapies which will enhance patient quality of life."

Prof Ullrich's longstanding expertise in molecular biology research is again being put to good use, having already resulted in some very successful therapeutic agents. For example, Herceptin, a drug he developed, is successfully used to treat metastasised breast cancer. The drug Sutent, which treats malignant tumours in the gastrointestinal tract (GIST) and renal cancer (MRCC) is also based on Ullrich's research work. In the case of both of the above drugs, the suppression of certain kinase activity with suitable inhibitors is central to the treatment.


'/>"/>

Contact: Markus Berninger
0049-892-909-1930
Max-Planck-Gesellschaft
Source:Eurekalert

Related biology news :

1. John P. Holdren addresses climate change, stressing need for international cooperation
2. ARS, industry cooperation yields device to detect insects in stored wheat
3. Leading entomologist to give talk at UCR on communication and cooperation in ant societies
4. HFSP President Arima and Secretary General Winnacker awarded for fostering cooperation with China
5. Nanyang Technological University and UK partners heightens cooperation in water industry
6. World-class innovation through international cooperation
7. T cell discovery shows promise for Type 1 diabetes treatment: UBC-CFRI study
8. Garlic oil shows protective effect against heart disease in diabetes
9. National study finds strong link between diabetes and air pollution
10. Biologists discover biochemical link between biological clock and diabetes
11. Women with diabetes having more C-sections and fetal complications: study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/9/2016)... , March 9, 2016  Crossmatch ® , ... enrollment solutions, today announced the addition of smart ... Altus multi-factor authentication platform. New contextual and ... to step-up security where it,s needed most — ... Washington, DC . --> ...
(Date:3/3/2016)... March 3, 2016  FlexTech, a SEMI Strategic Association ... Innovation, Research & Development, Leadership in Education, and, in ... the 9 th year of the FLEXI Awards ... and individuals from past years . Judging was ... pre-described set of criteria, by a panel of non-affiliated, ...
(Date:3/3/2016)... NOTTINGHAM, England and DE SOTO, ... , U.S.-based Stroke Detection Plus® to offer Oncimmune,s ... the risk assessment and early detection of lung cancer ... include large employers, unions and individuals. --> ... employers, unions and individuals. --> Oncimmune, a ...
Breaking Biology News(10 mins):
(Date:4/28/2016)... Boston, MA (PRWEB) , ... April 28, 2016 ... ... (EDT), Asymmetrex will deliver a talk on its first-in-class technologies for ... the 2016 Meeting on RNAiMicroRNA Biology to Reprogramming & CRISPR-based Genome ...
(Date:4/27/2016)... ... ... The Pittcon Organizing Committee is pleased to announce that Charles “Chuck” Gardner ... Committee since 1987. Since then, he has served in a number of key leadership ... both the program and exposition committees. In his professional career, Dr. Gardner is the ...
(Date:4/27/2016)... (PRWEB) , ... April 27, 2016 , ... ... that Jon Clark has joined the company as an Expert Consultant. Mr. ... for industry collaborations and managing the development of small molecule monographs based on ...
(Date:4/27/2016)... MedDay, a biotechnology company focused on the treatment of ... as Chairman of its Board of Directors. Catherine ... who contributed to the rapid development of the Company since ... her career in strategy consulting and investment banking in ...  She held C-Suite level roles in some of ...
Breaking Biology Technology: